C. Glenn Begley
C. Glenn Begley is a hematologist and oncologist who is the CEO of BioCurate, an Australia-based joint venture between the University of Melbourne and Monash University that was launched in 2016.[1] Previously, he worked at the California-based biotech company Akriveia Therapeutics as their chief scientific officer. His other previous positions include global head of hematology and oncology research at Amgen, senior vice president and chief scientific officer at TetraLogic Pharmaceuticals, and executive director of the Western Australian Institute of Medical Research.
He studied medicine at the University of Melbourne.[1] He is known for a study he co-authored in 2012 in which he found that only 6 out of 53 (11%) of landmark preclinical studies of cancer drugs could be reproduced.[2][3][4][5] He was elected to the American Society for Clinical Investigation in 2000.[6] Begley was elected Fellow of the Australian Academy of Health and Medical Sciences in 2015.[7]
References
- ^ a b "CEO Appointed". BioCurate. 30 April 2017. Retrieved 25 April 2018.
- ^ Begley, C. Glenn; Ellis, Lee M. (March 2012). "Drug development: Raise standards for preclinical cancer research". Nature. 483 (7391): 531–533. doi:10.1038/483531a. ISSN 0028-0836. PMID 22460880.
- ^ "How Mouse Studies Lead Medical Research Down Dead Ends". NPR. 8 April 2014. Retrieved 25 April 2018.
- ^ Zimmer, Carl (14 August 2012). "Good Scientist! You Get a Badge". Slate. Retrieved 25 April 2018.
- ^ Begley, Sharon (28 March 2012). "In cancer science, many "discoveries" don't hold up". Reuters. Retrieved 25 April 2018.
- ^ "C Glenn Begley". American Society for Clinical Investigation.
- ^ "Fellowship | AAHMS – Australian Academy of Health and Medical Sciences". www.aahms.org. Retrieved 25 June 2018.
External links
- C. Glenn Begley publications indexed by Google Scholar
  | This biographical article related to medicine in Australia is a stub. You can help Wikipedia by expanding it. |